Roundup Settlement Uncertainty: What Bayer’s $7.25 Billion Dispute Means for Your Cancer Claim
You are reading about Bayer’s stock dropping because the proposed $7.25 billion Roundup settlement has hit a wall, and the first thing you want to know is whether that is bad news for your case. It is not. It is the opposite. When plaintiffs seek to transfer a settlement to a federal court in California — the same court that has managed the Roundup litigation for years — it means the people fighting for cancer patients are pushing back against a deal that may undervalue what happened to you. The uncertainty you are seeing in the financial headlines is the sound of a negotiation that has not finished, not a door closing. Your case still has options. The question is which option is right for you, and that decision has a clock on it.
We are Attorney911 — The Manginello Law Firm. We handle toxic-tort and product-liability cases, and we are writing this for one person: someone who used Roundup, developed non-Hodgkin lymphoma or another cancer, and is now watching the settlement news and wondering whether to wait, whether to act, and whether the fight is still worth joining. It is. But the decision of how to proceed — settlement participation versus individual litigation — is irreversible, case-specific, and the most important strategic choice you will make. This page exists to give you the information to make it correctly.
What the Settlement Transfer Actually Means
Bayer AG shares fell roughly 5% in European trading after plaintiffs in the Roundup mass tort sought to transfer the proposed $7.25 billion settlement to a federal court in California. Bayer’s year-to-date stock loss approached 10% following the development. Those are financial facts. Here is what they mean in human terms.
The proposed settlement represents Bayer’s attempt to resolve claims by users of the glyphosate-based weedkiller who allege they developed non-Hodgkin lymphoma and other cancers. When plaintiffs seek to transfer that settlement to the federal court that has served as the central venue for the Roundup multidistrict litigation — the Northern District of California — they are signaling something specific: ongoing disputes over settlement terms, allocation, and judicial oversight. In plain language, the people who negotiated the deal on behalf of claimants are not satisfied that it delivers fair value, and they want a judge with deep familiarity with the litigation to oversee its structure and approval.
The federal multidistrict litigation for Roundup — formally MDL-2741, In re: Roundup Products Liability Litigation — has been centralized in the Northern District of California before Judge Vince Chhabria. As of mid-2026, the JPML’s pending-docket report shows thousands of actions consolidated there. California has served as the procedural hub for the litigation, and the proposed settlement transfer targets that same venue — a court known for sophisticated case management of complex mass torts and a judicial culture that has historically been receptive to product-safety claims.
What the transfer effort tells you, the individual claimant, is that the settlement framework is not a done deal. It is a proposal under pressure. And when a $7.25 billion aggregate settlement is under pressure, the per-claimant allocation — the amount each individual cancer patient would actually receive — is exactly what is being fought over. Many claimants and their counsel believe individual case values exceed the settlement’s per-claimant offer. Bellwether trials in California have demonstrated that juries, when presented with internal corporate documents and causation evidence, are willing to award substantial compensatory and punitive damages — figures that can dwarf what a structured settlement offers.
The strategic crossroads is real. Claimants must weigh guaranteed but potentially undervalued compensation through the settlement against the upside and risk of individual verdict-track litigation. That decision is irreversible. No general advice applies to every claimant. But the clock that governs the right to make that decision is running in every state, and it does not pause while the settlement is negotiated.
The Defendant: Bayer AG and Monsanto — the Corporate Structure
The company whose stock just fell is Bayer AG, the German pharmaceutical and agricultural conglomerate that acquired Monsanto Company in 2018 and assumed successor liability for Roundup-related claims. Monsanto is the original manufacturer and distributor of Roundup herbicide — the entity that designed, tested, marketed, and labeled the glyphosate formulation at issue. In the underlying product liability actions, Monsanto remains the named defendant, now backed by Bayer’s balance sheet.
This corporate structure matters to your case in several concrete ways. Bayer is one of the largest publicly traded companies in the world — a deep-pocket defendant with the resources to fund a global settlement, fight individual trials, or do both simultaneously. When Bayer acquired Monsanto, it inherited not just the product line but the liability — every claim, every internal document, every scientific dispute, and every regulatory battle that Monsanto had built over decades. Bayer’s settlement strategy is a corporate risk-containment exercise: the $7.25 billion proposal is designed to cap exposure, not to maximize per-claimant recovery. That is the structural tension the transfer motion exposes.
Potential downstream defendants may also exist in the supply chain — distributors and retailers who distributed Roundup to end-users. Depending on your jurisdiction and the product-labeling roles these entities played, separate failure-to-warn and distribution-chain liability claims may be available. Identifying every entity in the chain of commerce is part of building a complete case, and it is work that should begin early.
The Monsanto internal documents already produced through MDL discovery form the spine of the failure-to-warn and punitive damages cases. These include internal emails, regulatory submission drafts, and scientific publication strategies that plaintiffs allege demonstrate knowledge of glyphosate’s carcinogenic potential and a corporate strategy to influence regulatory assessments and public perception. The corporate document set is the engine that has produced significant verdicts in bellwether trials — and it is the reason the settlement-versus-litigation decision is not a question of whether the evidence exists, but of whether your individual case value is better recognized in a structured settlement or in front of a jury.
The Regulatory Battle: FIFRA, the EPA, and the Science Split
Roundup is regulated at the federal level under the Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA), which governs pesticide registration, labeling, and sale in the United States. The U.S. Environmental Protection Agency registers glyphosate under FIFRA and has historically taken the position that glyphosate is “not likely” carcinogenic to humans. That EPA position is the defendant’s first line of defense — Monsanto and Bayer argue that they complied with federal labeling requirements and that the EPA’s assessment should govern.
But there is a second scientific voice, and it is the one plaintiffs’ causation experts rely on. In 2015, the International Agency for Research on Cancer (IARC) — the World Health Organization’s specialized cancer agency — classified glyphosate as “probably carcinogenic to humans.”
The International Agency for Research on Cancer (IARC) classified glyphosate as “probably carcinogenic to humans” in 2015, providing a critical regulatory anchor for plaintiff causation experts.
The split between the EPA’s “not likely” position and IARC’s “probably carcinogenic” classification is the scientific battleground of every Roundup case. The defense points to the EPA; the plaintiff points to IARC. The jury decides which science to believe.
California adds another regulatory layer. The state’s Office of Environmental Health Hazard Assessment listed glyphosate under Proposition 65 as a chemical known to cause cancer, requiring warnings for chemicals recognized as carcinogenic. This state-level listing creates additional regulatory pressure on glyphosate products and provides a California-specific failure-to-warn dimension that does not exist in every state.
The preemption question — whether FIFRA compliance blocks state-law failure-to-warn claims — is the threshold legal fight in this litigation. Established Supreme Court preemption doctrine holds that FIFRA compliance does not automatically preempt state-law failure-to-warn claims. But that doctrine is now being tested. A case called Monsanto Company v. Durnell was argued before the U.S. Supreme Court in spring 2026, asking whether FIFRA expressly preempts state-law failure-to-warn claims when the EPA did not require a cancer warning. A decision is pending. How the Court rules could reshape every Roundup claim in the country — either green-lighting state failure-to-warn lawsuits or potentially narrowing them. Anyone with a Roundup claim should understand that this ruling is coming and that moving quickly, rather than waiting to see how the law settles, may be the safer course.
California Product Liability Law: Your Strongest Forum
The proposed settlement transfer targets a federal court in California for good reason. California serves as the procedural hub for the Roundup MDL, and California’s product liability doctrine is among the most developed in the nation.
California follows strict liability for both design defect and warning defect claims. For design defect, California applies both a risk-benefit test and a consumer-expectation test — giving plaintiffs two paths to prove the product was defectively designed. For failure-to-warn claims, California imposes a sophisticated duty-to-warn standard on manufacturers: a company that knows or should know of a carcinogenic risk must warn consumers, and the adequacy of that warning is judged by what a reasonable consumer would need to know to make an informed decision about using the product.
California does not impose statutory caps on compensatory damages in personal injury or wrongful death cases, and punitive damages are available upon a showing of malice, oppression, or fraud by clear and convincing evidence.
That last sentence is one of the most important facts on this page for a Roundup claimant. Many states cap non-economic damages — pain and suffering, loss of enjoyment of life — at arbitrary statutory ceilings that can gut a cancer case. California has no such caps. A jury in California can award the full measure of human loss without a statutory ceiling cutting it down.
And punitive damages — the damages designed to punish and deter conduct that goes beyond negligence — are available in California upon a showing of malice, oppression, or fraud by clear and convincing evidence. The Monsanto internal documents, which plaintiffs allege show decades-long knowledge of carcinogenic potential and a corporate strategy to influence regulatory assessments, are exactly the kind of evidence that supports a punitive damages submission. When bellwether juries in California have seen those documents, they have responded with substantial punitive awards.
But there is a critical procedural point every claimant must understand. In the MDL context, the transferee court applies its own procedural rules, but substantive law is borrowed from each plaintiff’s home state under the Erie doctrine. This means the applicable statute of limitations, comparative fault rules, and damage frameworks vary plaintiff by plaintiff. A claimant in Texas has Texas substantive law applied to their claim; a claimant in California has California law. The forum matters, but so does your home state’s law. Confirm the current rule for your specific jurisdiction — do not assume that what applies in California applies to you.
The Medicine: Non-Hodgkin Lymphoma and the Causation Fight
The primary injury in the Roundup mass tort is non-Hodgkin lymphoma (NHL) — a cancer of the lymphatic system that begins in lymphocytes, the white blood cells that help the body fight infection. NHL is not a single disease but a group of more than 70 subtypes, including diffuse large B-cell lymphoma (the most common aggressive form), follicular lymphoma (the most common indolent form), mantle cell lymphoma, and others. Each subtype has a different prognosis, treatment protocol, and survival curve.
The mechanism plaintiffs allege: glyphosate exposure, absorbed through the skin during application or inhaled during spraying, enters the bloodstream and damages the DNA of lymphocytes over time, leading to malignant transformation — the uncontrolled growth of abnormal lymphocytes that forms tumors in lymph nodes, spleen, bone marrow, and other lymphatic tissue. The latency period between exposure and diagnosis can be years, which is why many Roundup users never connected their cancer to the weedkiller until the litigation brought the science to public attention.
The diagnostics are well established: physical examination of lymph nodes, blood tests (complete blood count, lactate dehydrogenase, flow cytometry), imaging (CT, PET), and ultimately a lymph node biopsy with pathology and immunohistochemistry to confirm the NHL subtype. The pathology report is the foundational medical document — it names the cancer, stages it, and identifies the cell type, all of which drive both treatment and the causation analysis.
Treatment depends on subtype and stage but commonly includes:
- Chemotherapy regimens — most notably R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) for aggressive forms
- Radiation therapy — targeted to lymph node regions where tumors are concentrated
- Immunotherapy — monoclonal antibody treatments that harness the immune system against lymphoma cells
- Stem cell transplant — autologous (using the patient’s own stem cells) or allogeneic (donor cells) for relapsed or high-risk cases
- Ongoing surveillance — regular scans, blood work, and oncology follow-up for years, sometimes for life, because NHL can relapse
The costs are enormous. A single course of R-CHOP chemotherapy, imaging, supportive care, and follow-up can run well into six figures. A stem cell transplant can exceed half a million dollars. Lost wages during treatment — which can last months — compound the financial damage. And for patients whose cancer relapses, the treatment cycle begins again.
The proof problem the defense exploits is causation. Non-Hodgkin lymphoma has many causes — genetic predisposition, viral infections (including Epstein-Barr and HTLV-1), immunosuppression, other chemical exposures, and a large percentage of cases classified as “idiopathic” (no identifiable cause). The defense argues that the plaintiff cannot prove glyphosate caused this cancer rather than something else. The counter lives in the exposure history and the expert testimony: a plaintiff who used Roundup regularly for years — mixing, spraying, and cleaning equipment without protective gear — has a cumulative dose that, combined with IARC’s “probably carcinogenic” classification and epidemiological studies showing elevated NHL risk in heavy glyphosate users, supports specific causation. The oncologist’s causation opinion, tied to the plaintiff’s exposure timeline and the peer-reviewed literature, is the bridge between general causation (glyphosate can cause NHL) and specific causation (glyphosate caused this plaintiff’s NHL).
For families who have lost a loved one to NHL, the wrongful death claim carries different damage elements: funeral expenses, loss of financial support, loss of consortium, and society-and-comfort damages. The survival action — for the victim’s pre-death pain and suffering — may also be available depending on the state. The survival-versus-wrongful-death damage split varies by the plaintiff’s home state, with some jurisdictions preserving pre-death pain-and-suffering damages in survival actions while others limit recovery to economic losses alone. Confirm the current rule in your jurisdiction.
The Evidence Clock: What Exists and How Fast It Disappears
Every mass tort case is a race against evidence destruction, and Roundup is no exception. The proof of your case lives in five categories of records — each with a different custodian, a different rate of decay, and a different urgency for preservation.
Monsanto corporate documents, emails, and research files. These are the heart of the failure-to-warn and punitive damages cases — internal emails, regulatory submission drafts, scientific publication strategies, and research files that plaintiffs allege demonstrate knowledge of carcinogenic risk and efforts to shape the scientific record. Many have been produced through MDL discovery, but ongoing privilege disputes and document repositories require active monitoring. Corporate document retention policies and the subsequent acquisition by Bayer create spoliation risk for newly identified custodians. These documents are largely in the defendant’s control — the path to them runs through litigation or settlement participation, not through a public records request.
Roundup product labels, safety data sheets, and marketing materials. These demonstrate the evolution — or absence — of cancer warnings across product generations and establish what consumers actually saw at the point of use. Historical labels are increasingly difficult to source as products are reformulated and packaging changes. Third-party archival collections, retained product containers, and photographs of packaging from the relevant time period are the substitutes. If you still have a Roundup container from the years you used it, do not discard it — it is evidence of what warning (or lack of warning) you received.
Claimant medical records. Your pathology reports, treatment histories, and oncologist causation opinions are the foundation of specific causation. These records must be assembled before the limitations clock expires in your home state. The oncologist’s causation opinion — a formal letter or report from your treating physician or a retained expert linking your glyphosate exposure to your NHL diagnosis — requires early retention to meet expert disclosure deadlines. Your medical records are the one category of evidence you can control directly. Request complete copies of your oncology file, including pathology slides, treatment summaries, imaging reports, and follow-up notes.
Claimant exposure history documentation. This is the category most people neglect and the one that fades fastest. Purchase receipts, agricultural-use logs, occupational records, and witness statements quantify your cumulative glyphosate dose and establish the temporal relationship between exposure and cancer diagnosis. Receipts degrade or are discarded. Product containers are thrown away. Memory of usage patterns — how often you sprayed, how you mixed the concentrate, whether you wore gloves, how long you spent in the sprayed area — fades with each passing year. Exposure affidavits should be taken while claimants are able to recall detail. If you used Roundup at home, write down everything you remember: the years, the frequency, the size of the area treated, how you applied it, what protective equipment you wore (or did not wear), and whether you ever got it on your skin or inhaled the spray. If you used it occupationally — as a landscaper, farmer, groundskeeper, or grounds crew worker — employment records, pesticide application logs, and co-worker statements can corroborate your exposure.
IARC monograph, EPA registration filings, and California Proposition 65 records. These public records establish the regulatory and scientific framework for general causation. They are public and durable, but they require organized compilation and expert interpretation for trial presentation. Your attorney should be assembling these from the beginning, but the public-record science does not expire — your personal evidence does.
The preservation letter — a formal demand that the defendant and any third-party custodians freeze relevant evidence — is the tool that converts a routine retention schedule into a litigation hold. In a mass tort like Roundup, where corporate documents are the punitive damages engine, the preservation letter is not a formality. It is the first shot in the evidence war.
The Money: What a Roundup Case Is Actually Worth
The proposed $7.25 billion aggregate settlement suggests an intended per-claimant allocation framework — but the plaintiff transfer effort signals that many claimants and counsel believe individual case values exceed what the settlement offers per person. Here is how individual case value is actually built.
Settlement-track cases — claims with moderate exposure history and treatable cancer that enter a structured settlement framework — may resolve in the range of $50,000 to $150,000 per qualifying claimant. These are the cases the settlement framework is designed to capture: predictable, documented, but not the cases that produce headline verdicts.
Verdict-track cases — individual cases with prolonged heavy exposure, aggressive non-Hodgkin lymphoma with significant treatment burden, and strong punitive damages evidence from the Monsanto internal documents — can reach $5,000,000 to $50,000,000 or more. Bellwether trials in California have demonstrated jury willingness to award substantial compensatory and punitive damages when the internal corporate documents are presented and the causation evidence is strong.
Individual case value is driven by five factors:
-
Exposure duration and intensity. A homeowner who sprayed Roundup on weekend weeds for a decade has a different exposure profile than a professional landscaper who mixed and applied concentrated glyphosate daily for twenty years. The dose reconstruction — how much, how often, how concentrated, how absorbed — is the foundation of the causation case and a primary driver of value.
-
Cancer subtype and prognosis. An indolent follicular lymphoma that responds to treatment and enters remission has a different damages profile than an aggressive diffuse large B-cell lymphoma requiring stem cell transplant, or a cancer that has relapsed multiple times. The pathology report, the treatment history, and the prognosis drive the medical-cost and pain-and-suffering components.
-
Age and earning capacity of the claimant. A 45-year-old professional who loses years of income during treatment and faces reduced earning capacity going forward has a larger economic-loss claim than a retiree. The forensic economist projects lost earnings, lost fringe benefits (which the Bureau of Labor Statistics measures at roughly 30% of total compensation for private-industry workers), and lost household services.
-
Jurisdictional damage framework. California imposes no caps on compensatory damages and allows punitive damages on clear and convincing evidence of malice, oppression, or fraud. Other states cap non-economic damages, bar punitive damages, or limit survival actions to economic losses only. Your home state’s law — applied through the Erie doctrine even in the MDL — can dramatically change the value of an identical injury.
-
The strength of the documentary evidence chain. The Monsanto internal documents showing pre-litigation knowledge of carcinogenic risk are the punitive damages multiplier. A case with strong exposure documentation, clear causation, and compelling corporate-knowledge evidence is worth multiples of a case with the same injury but thin exposure proof.
The honest framing: the $7.25 billion settlement is a corporate risk-containment tool. It is designed to close files at a predictable cost per claimant. The verdict track is designed to prove what an individual case is actually worth in front of a jury. The decision between the two is the single most important strategic choice a Roundup claimant makes, and it should be made with full information about your specific exposure, your specific cancer, your specific jurisdiction, and the specific evidence available to prove your case. Past results depend on the facts of each case and do not guarantee future outcomes.
The Defense Playbook: What Monsanto and Bayer Will Try
The defense in Roundup litigation is sophisticated, well-funded, and has a documented playbook. Here are the plays and the counters.
Play 1: “The EPA says glyphosate is not likely carcinogenic.” The defense leads with the EPA’s registration position and argues that Monsanto complied with federal labeling requirements. The counter: IARC — the world’s leading cancer research agency — classified glyphosate as “probably carcinogenic to humans” in 2015, and California listed it under Proposition 65. The EPA’s position is one regulatory voice, not the final scientific word, and the jury decides which agency’s science is more credible. The EPA’s own internal scientific disputes and the controversy surrounding its glyphosate assessment are part of the plaintiff’s rebuttal.
Play 2: “Non-Hodgkin lymphoma has many causes; you cannot prove Roundup caused YOUR cancer.” The defense exploits the fact that NHL is a multifactorial disease with a large percentage of idiopathic cases. The counter: specific causation is proven through dose reconstruction (documented exposure history), the IARC classification (general causation), epidemiological studies showing elevated NHL risk in heavy glyphosate users, and the treating oncologist’s or retained expert’s causation opinion tying the exposure timeline to the diagnosis. The defense’s “you can’t prove it” argument is an evidentiary challenge, not a legal bar — it goes to the weight of the evidence, not its admissibility.
Play 3: “FIFRA preempts your state-law failure-to-warn claim.” The defense argues that because the EPA approved the Roundup label without requiring a cancer warning, federal law blocks state-law claims about the missing warning. The counter: established Supreme Court preemption doctrine holds that FIFRA compliance does not automatically preempt state-law failure-to-warn claims. But this is the live legal fight — Monsanto Co. v. Durnell is pending before the U.S. Supreme Court, and a decision could reshape the preemption landscape. The honest move is to file now, while the current doctrine is favorable, rather than wait for a ruling that could narrow the path.
Play 4: “Your statute of limitations has expired.” The defense argues that the time to sue has passed because the cancer was diagnosed years ago. The counter: many states apply a discovery rule for latent diseases — the clock does not start when you were exposed, or even when you were diagnosed, but when you discovered or reasonably should have discovered the connection between your exposure and your cancer. For many Roundup claimants, that connection was not apparent until the litigation and the IARC classification brought the science to public attention. The discovery rule is not available in every state, and some states impose an outer statute-of-repose deadline that can cut off a claim even before discovery. Confirm the rule in your state — this is not a place for assumptions.
Play 5: “The settlement is fair — take the guaranteed money.” The defense frames the settlement as a generous offer and warns that individual trials carry risk. The counter: bellwether verdict outcomes demonstrate that juries, when presented with the internal corporate documents and causation evidence, have awarded amounts that can substantially exceed the settlement’s per-claimant allocation. The settlement is a risk-management tool for the defendant, not a ceiling on what your case is worth. The decision to accept or reject the settlement should be based on an individualized evaluation of your exposure, your cancer, your jurisdiction, and your evidence — not on a one-size-fits-all framework.
The Proof Story: How a Roundup Case Is Actually Built
Here is the chronological walk of how a Roundup case is constructed, from the day you call to the day a number is on the table.
Week one: the preservation letter goes out. The day you contact counsel, a written demand goes to Monsanto/Bayer and any third-party custodians ordering them to freeze all evidence related to your claim — internal documents touching your exposure period, product labels and safety data sheets from the years you used Roundup, and any records specific to your interaction with the product. This letter converts routine retention schedules into litigation holds and creates spoliation leverage if evidence later “disappears.”
Weeks one through four: the medical record is assembled. Your complete oncology file is requested and reviewed — pathology reports, treatment summaries, imaging, chemotherapy records, follow-up notes, and prognosis opinions. The pathology report is the foundation: it names the NHL subtype, the stage, the cell type, and the aggressiveness. From this, the causation expert will work.
Weeks two through eight: the exposure history is documented. This is the hardest and most time-sensitive work. You sit down and reconstruct your entire Roundup use history: the years, the frequency, the product formulation (ready-to-use versus concentrate), the application method (sprayer, backpack, hose-end), the area treated, the protective equipment worn (or not worn), and any incidents of direct skin contact or inhalation. If you used Roundup occupationally, employment records, pesticide application logs, and co-worker statements are gathered. If you used it at home, receipts, photographs of the property, and family-member witness statements are assembled. An exposure affidavit — a sworn statement of your usage history — is prepared while your memory is fresh.
Months two through six: expert retention and report preparation. An oncologist or hematologist is retained to provide a causation opinion — a formal report linking your documented glyphosate exposure to your NHL diagnosis, relying on the IARC classification, the epidemiological literature, and your specific exposure-dose timeline. An epidemiologist or toxicologist may be retained to address general causation. The experts’ reports must be exchanged according to the court’s expert-disclosure schedule, which varies by jurisdiction and whether the case is in the MDL or in an individual court.
Months three through twelve: discovery and depositions. Written discovery (interrogatories, requests for production) forces the defendant to produce internal documents, regulatory correspondence, and scientific research files. Depositions of corporate witnesses — the scientists, the regulatory affairs personnel, the marketing executives — put Monsanto’s knowledge and conduct on the record under oath. The corporate document set already produced through the MDL is the starting library; case-specific discovery fills the gaps.
Month twelve onward: mediation, settlement evaluation, or trial preparation. With the document production, the expert reports, and the depositions complete, the case is positioned for a realistic settlement evaluation or trial preparation. Mediation of individual cases should be timed after key document production and expert reports are exchanged but before trial-date pressure drives defense valuations artificially low. If the case proceeds to trial, the bellwether model — individual trials with the full corporate-document presentation — has demonstrated that juries respond to the evidence.
The number at the end is built from all of it: the exposure dose, the cancer subtype and prognosis, the treatment costs, the lost earnings, the pain and suffering, the punitive damages evidence, and the jurisdictional framework that governs what is recoverable and what is capped.
Your First Steps: What to Do Now
If you used Roundup and were diagnosed with non-Hodgkin lymphoma — or if you lost a family member to NHL who was a regular Roundup user — the steps you take in the coming weeks matter.
Step 1: Secure your medical records. Request complete copies of your oncology file from every treating facility — pathology reports, treatment summaries, imaging studies, chemotherapy records, follow-up notes, and prognosis opinions. These are your evidence, and you have a legal right to them. Do not assume your doctor will keep them forever — medical-records retention varies by facility and state, and records can be purged on routine schedules.
Step 2: Document your exposure history while your memory is fresh. Write down everything you can recall about your Roundup use. The years. The frequency (weekly? monthly? seasonally?). The product type (Roundup ready-to-use? Concentrate? Extended control?). The application method. The size of the area treated. Whether you mixed concentrate. Whether you wore gloves, a mask, or protective clothing. Whether you ever got it on your skin. Whether you ever inhaled the spray. If family members can corroborate your usage, ask them to write down what they remember too. Memory fades — the affidavit you can produce today will be more detailed and more credible than the one you try to produce two years from now.
Step 3: Preserve any physical evidence. If you still have Roundup containers, product packaging, or old receipts, do not discard them. Photograph the labels — they show what warning (or absence of warning) you received at the time of use. The product label is a piece of evidence that cannot be reconstructed after the container is gone.
Step 4: Check the statute of limitations in your state. California’s two-year personal injury statute of limitations is a common benchmark, but it does not govern out-of-state plaintiffs whose claims may be filed in their home courts. Many states have two- or three-year personal injury limitations periods. The discovery rule — which may start the clock when you discovered or should have discovered the connection between your cancer and Roundup, rather than when you were exposed or diagnosed — may extend the window in some states. But some states impose an outer statute-of-repose deadline that can cut off a claim regardless of discovery. The current limitations rule for your specific jurisdiction must be confirmed — this is not a place for guessing. The deadline is real, it is running, and missing it ends your case permanently regardless of how strong the evidence is.
Step 5: Do not sign anything from the settlement administrator without understanding what it means. If you receive a settlement offer or participation form related to the $7.25 billion framework, do not sign them without an individualized evaluation of whether the settlement’s per-claimant allocation is fair for your specific case. The decision to participate in the settlement versus pursuing individual litigation is irreversible. Once you sign a release, your claim is closed — you cannot later decide to take your case to trial instead.
Step 6: Get a case evaluation. The consultation is free. The evaluation is specific to your exposure, your cancer, your jurisdiction, and your evidence. The decision you make — settlement or individual litigation — should be made with full information, not in reaction to a news headline.
Frequently Asked Questions
Is the Roundup settlement falling apart?
The proposed $7.25 billion settlement has not fallen apart — it is under pressure. Plaintiffs seeking to transfer the settlement to California federal court are signaling disputes over settlement terms, per-claimant allocation, and judicial oversight. The transfer effort means the fight for fair value is ongoing. The settlement framework may be restructured, approved as proposed, or replaced by a different approach. Your individual case is not stalled — it is a signal that plaintiff advocates are working to ensure the settlement delivers fair value rather than serving primarily as a corporate risk-containment tool.
I used Roundup and have non-Hodgkin lymphoma. Do I still have time to file?
The answer depends on your state’s statute of limitations and whether the discovery rule applies. California’s two-year personal injury deadline is a common benchmark, but many states have different periods — two years, three years, or longer. The discovery rule, which may start the clock when you discovered or should have discovered the connection between Roundup and your cancer, can extend the window in some states. However, some states impose an outer statute-of-repose deadline that can bar a claim regardless of when you discovered the connection. The only safe move is to confirm the current deadline for your specific state — and to do it soon, because the clock is running.
Should I join the settlement or pursue an individual lawsuit?
This is the most important strategic decision in a Roundup case, and no general advice applies to every claimant. The settlement offers guaranteed compensation but may undervalue your individual case — particularly if you had heavy, prolonged exposure, an aggressive cancer subtype, significant treatment costs, and strong evidence of Monsanto’s pre-litigation knowledge. Individual verdict-track litigation offers the potential for higher recovery but carries trial risk and takes longer. The decision should be based on an individualized evaluation of your exposure history, your cancer subtype and prognosis, your jurisdiction’s damage framework, the strength of your evidence, and your personal risk tolerance. It is irreversible — once you sign a settlement release, you cannot pursue individual litigation. Get a case evaluation before deciding.
What if my loved one died from non-Hodgkin lymphoma after using Roundup?
Surviving family members may bring a wrongful death claim alleging that Roundup exposure caused or contributed to the death. Wrongful death damages include funeral expenses, loss of financial support, loss of consortium, and society-and-comfort damages — though the specific elements available vary by state. A separate survival action may preserve the victim’s pre-death pain-and-suffering damages, depending on the jurisdiction. The statute of limitations for wrongful death also varies by state and may differ from the personal injury deadline. If you lost a family member to NHL and they were a regular Roundup user, the time to evaluate a claim is now — the evidence of their exposure history (receipts, employment records, co-worker statements) is even more vulnerable to loss when the person who lived it is no longer here to testify.
Does the EPA’s position that glyphosate is “not likely” carcinogenic hurt my case?
The EPA’s position is the defendant’s first line of defense, but it is not the final scientific word. IARC — the World Health Organization’s cancer agency — classified glyphosate as “probably carcinogenic to humans” in 2015. California listed glyphosate under Proposition 65 as a chemical known to cause cancer. The split between the EPA and IARC is the scientific battleground of every Roundup case, and the jury decides which science is more credible. The EPA’s position is evidence the defense presents; it is not a bar to your claim.
What is the FIFRA preemption case before the Supreme Court?
A case called Monsanto Company v. Durnell was argued before the U.S. Supreme Court in spring 2026. The question is whether FIFRA — the federal pesticide-labeling law — expressly preempts state-law failure-to-warn claims when the EPA did not require a cancer warning on the Roundup label. A decision is pending. If the Court rules that FIFRA preempts state failure-to-warn claims, it could narrow the path for some Roundup claims. If it rules the other way, it green-lights the litigation. The established doctrine currently holds that FIFRA compliance does not automatically preempt state-law failure-to-warn claims — but the Durnell decision could change that. Moving quickly, while the current doctrine is favorable, may be the safer course.
How much is my Roundup case worth?
Case value depends on five factors: your exposure duration and intensity, your cancer subtype and prognosis, your age and earning capacity, your state’s damage framework (caps or no caps, punitive availability), and the strength of the documentary evidence chain — particularly the Monsanto internal documents showing pre-litigation knowledge of carcinogenic risk. Settlement-track cases with moderate exposure and treatable cancer may resolve in the $50,000 to $150,000 range. Verdict-track cases with heavy exposure, aggressive cancer, and strong punitive damages evidence can reach $5,000,000 to $50,000,000 or more. These are not predictions — they are the range the existing bellwether record and settlement framework suggest. Past results depend on the facts of each case and do not guarantee future outcomes. An honest evaluation requires knowing your specific facts.
What evidence do I need to preserve?
Five categories: (1) your complete medical records — pathology reports, treatment histories, oncologist opinions; (2) your exposure history — purchase receipts, usage patterns, occupational records, witness statements; (3) any physical evidence — Roundup containers, product labels, photographs; (4) your employment records if you used Roundup occupationally; and (5) any correspondence you have received about the settlement or the litigation. The exposure history is the most time-sensitive — memory fades, receipts are discarded, and containers are thrown away. Write down everything you remember about your Roundup use now, while the details are still available to you.
Why Attorney911
We are The Manginello Law Firm, PLLC — operating as Attorney911, Legal Emergency Lawyers. We have been handling personal injury, toxic tort, and wrongful death cases for over two decades. Ralph P. Manginello, our managing partner, has been licensed and practicing for 27+ years, including in federal court. He was a journalist before he was a lawyer — he knows how to find the story the documents tell, and he knows how to tell it to a jury. Lupe Peña, our associate attorney, spent years inside a national insurance-defense firm — the rooms where claims like yours are priced, devalued, and denied. He sat across the table from the adjusters and their software. He knows how claim valuation works from the inside — the reserve-setting, the IME-doctor selection, the delay tactics — and now he uses that knowledge for injured clients. He conducts full consultations in Spanish without an interpreter, and we serve your family fully in both languages. Hablamos Español.
We work on contingency. We do not get paid unless we win your case. The consultation is free, and it is specific to your situation — your exposure, your cancer, your state’s law, and your evidence. Call us at 1-888-ATTY-911 (1-888-288-9911). We have live staff 24 hours a day, 7 days a week — not an answering service. If you are dealing with a Roundup claim, the settlement uncertainty in the headlines is not a reason to wait. It is a reason to understand your options before the clock and the evidence work against you.
This page is legal information, not legal advice. Every case is different. The facts of your exposure, your diagnosis, and your jurisdiction will determine what your claim is worth and how long you have to pursue it. Contacting us is free and confidential. Past results depend on the facts of each case and do not guarantee future outcomes.
1-888-ATTY-911. Free consultation. No fee unless we win.